Advertisement
Mayo Clinic Proceedings Home

Relative Survival With Early-Stage Breast Cancer in Screened and Unscreened Populations

Published:November 03, 2022DOI:https://doi.org/10.1016/j.mayocp.2022.08.006

      Abstract

      Relative survival and disease-specific survival are two statistics that measure net survival from a cancer diagnosis, excluding other causes of death. In most cases, these two rates are comparable. However, in some cancer types for which cancer screening is performed, relative survival is often greater than disease-specific survival. This divergence has been attributed to mechanisms such as the “healthy user effect” and overdiagnosis of indolent tumors detected by screening. Using relative survival rate as a marker of these mechanisms, we examined the association of breast cancer screening with relative survival rates for women diagnosed with early-stage breast cancer. In population-based data from the National Cancer Institute’s Surveillance, Epidemiology and End Results registry, we examined relative survival rates in women diagnosed with stage I breast cancer or ductal carcinoma in situ who were in highly screened vs less-highly screened groups, based on time period, age group, and insurance status. In this analysis, relative survival rates for early-stage breast cancer were higher than disease-specific survival, even exceeding 100% in populations experiencing higher rates of screening (ie, women diagnosed during the era of widespread uptake of mammography, age older than 40 years, and women with health insurance coverage). The favorable outcomes observed in screen-detected breast cancers are at least in part attributable to the healthy user effect and overdiagnosis of indolent tumors. Therefore, survival rates may not accurately reflect the effectiveness of cancer screening. These findings have implications for counseling of patients and future clinical studies of active monitoring approaches in breast cancer.

      Abbreviations and Acronyms:

      DCIS (ductal carcinoma in situ), SEER (Surveillance, Epidemiology and End Results Program)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Howlader N.
        • Ries L.A.G.
        • Mariotto A.B.
        • Reichman M.E.
        • Ruhl J.
        • Cronin K.A.
        Improved estimates of cancer-specific survival rates from population-based data.
        J Natl Cancer Inst. 2010; 102: 1584-1598
        • Makkar N.
        • Ostrom Q.T.
        • Kruchko C.
        • Barnholtz-Sloan J.S.
        A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations.
        Cancer Med. 2018; 7: 4773-4780
        • Henson D.E.
        • Ries L.A.
        The relative survival rate.
        Cancer. 1995; 76: 1687-1688
        • Shrank W.H.
        • Patrick A.R.
        • Alan Brookhart M.
        Healthy user and related biases in observational studies of preventive interventions: a primer for physicians.
        J Gen Intern Med. 2011; 26: 546-550
        • Davies L.
        • Petitti D.B.
        • Martin L.
        • Woo M.
        • Lin J.S.
        Defining, estimating, and communicating overdiagnosis in cancer screening.
        Ann Intern Med. 2018; 169: 36-43
        • Welch H.G.
        • Kramer B.S.
        • Black W.C.
        Epidemiologic signatures in cancer.
        N Engl J Med. 2019; 381: 1378-1386
        • Marcadis A.R.
        • Marti J.L.
        • Ehdaie B.
        • Hakimi A.A.
        • Davies L.
        • Morris L.G.T.
        Characterizing relative and disease-specific survival in early-stage cancers.
        JAMA Intern Med. 2020; 180: 461-463
      1. Table 33. Use of mammography among women aged 40 and over, by selected characteristics: United States, selected years 1987-2015.
        https://www.cdc.gov/nchs/fastats/mammography.htm
        Date: 2015
        Date accessed: December 30, 2020
        • Cho H.
        • Howlader N.
        • Mariotto A.B.
        • Cronin K.A.
        Estimating relative survival for cancer patients from the SEER program using expected rates based on Edereer I versus Ederer II method.
        (Accessed April 11, 2020.)
      2. (Accessed April 11, 2020.)
      3. History of ACS Recommendations for the Early Detection of Cancer in People Without Symptoms. Published July 30, 2020.
        • Qin J.
        • White M.C.
        • Sabatino S.A.
        • Febo-Vázquez I.
        Mammography use among women aged 18–39 years in the United States.
        Breast Cancer Res Treat. 2018; 168: 687-693
        • Sabatino S.A.
        • Coates R.J.
        • Uhler R.J.
        • Breen N.
        • Tangka F.
        • Shaw K.M.
        Disparities in mammography use among us women aged 40-64 years, by race, ethnicity, income, and health insurance status, 1993 and 2005.
        Med Care. 2008; 46: 692-700
        • Sabatino S.A.
        • Thompson T.D.
        • Richardson L.C.
        • Miller J.
        Health insurance and other factors associated with mammography surveillance among breast cancer survivors: results from a national survey.
        Med Care. 2012; 50: 270-276
        • Welch H.G.
        • Black W.C.
        Overdiagnosis in cancer.
        J Natl Cancer Inst. 2010; 102: 605-613
        • Bleyer A.
        • Welch H.G.
        Effect of three decades of screening mammography on breast-cancer incidence.
        N Engl J Med. 2012; 367: 1998-2005
        • Marcadis A.R.
        • Davies L.
        • Marti J.L.
        • Morris L.G.T.
        Racial disparities in cancer presentation and outcomes: the contribution of overdiagnosis.
        JNCI Cancer Spectr. 2020; 4: pkaa001
        • Hwang E.S.
        • Hyslop T.
        • Lynch T.
        • et al.
        The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).
        BMJ Open. 2019; 9e026797
        • Kanbayashi C.
        • Thompson A.M.
        • Hwang E.S.S.
        • et al.
        The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA).
        J Clin Oncol. 2019; 37 (TPS603-TPS603)